| Literature DB >> 27278453 |
Salma Oktaria1,2, Evita Halim Effendi3, Wresti Indriatmi3, Colette L M van Hees4, Hok Bing Thio4, Emmy Soedarmi Sjamsoe-Daili3.
Abstract
BACKGROUND: The clinical spectrum of leprosy is dependent on the host immune response against Mycobacterium leprae or the newly discovered Mycobacterium lepromatosis antigen. Helminth infections have been shown to affect the development of several diseases through immune regulation and thus may play a role in the clinical manifestations of leprosy and leprosy reactions. The purpose of this study is to determine the proportion of helminth infections in leprosy and its association with the type of leprosy and type 2 leprosy reaction (T2R).Entities:
Keywords: Helminth coinfection; Type 2 leprosy reaction; Type of leprosy
Mesh:
Year: 2016 PMID: 27278453 PMCID: PMC4898373 DOI: 10.1186/s12879-016-1593-0
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Demographic features of study participants between October 2013 and April 2014 (n = 81)
| No | Demographic features | Leprosy type n (%) | Total n (%) | |
|---|---|---|---|---|
| Paucibacillary ( | Multibacillary ( | |||
| 1 | Gender | |||
| • Male | 13 (65.0) | 54 (88.5) | 67 (82.7) | |
| • Female | 7 (35.0) | 7 (11.5) | 14 (17.3) | |
| 2 | Age groups | |||
| • 18–29 years | 6 (30.0) | 22 (36.1) | 28 (34.6) | |
| • 30–44 years | 9 (45.0) | 34 (55.7) | 43 (53.1) | |
| • 45–60 years | 5 (25.0) | 5 (8.2) | 10 (12.3) | |
| 3 | Educational level | |||
| • Low | 6 (30.0) | 23 (37.7) | 29 (35.8) | |
| • Middle | 11 (55.0) | 34 (55.7) | 45 (55.6) | |
| • High | 3 (15.0) | 4 (6.6) | 7 (8.6) | |
Clinical features of study participants between October 2013 and April 2014 (n = 81)
| No. | Clinical features | n | Percentage (%) |
|---|---|---|---|
| 1. | Leprosy type (Ridley & Jopling) | ||
| • Indeterminate | 0 | 0 | |
| • TT | 1 | 1.2 | |
| • BT | 19 | 23.5 | |
| • BB | 2 | 2.5 | |
| • BL | 49 | 60.5 | |
| • LL | 10 | 12.3 | |
| 2. | Leprosy type | ||
| • PB | 20 | 24.7 | |
| • MB | 61 | 75.3 | |
| 3. | Status of medication | ||
| • On fourth months of MDT-WHO until completion of treatment | 61 | 75.3 | |
| • RFT ≤ 6 months | 11 | 13.6 | |
| • RFT > 6 months-1 year | 9 | 11.1 | |
| 4. | History of T2R | ||
| • No | 50 | 61.7 | |
| • Yes | 31 | 38.3 | |
| 5. | Onset of T2R | ||
| • Before MDT-WHO treatment | 8 | 25.8 | |
| • During MDT-WHO treatment | 17 | 54.8 | |
| • After completion of MDT-WHO treatment | 6 | 19.4 | |
| 6. | Duration of corticosteroid therapy for T2R | ||
| • ≤ 12 weeks | 14 | 45.2 | |
| • > 12 weeks | 17 | 54.8 |
Clinical features of helminth-positive participants (n = 11)
| Participant number | Type of leprosy | Parasites | Intensity of infection | |
|---|---|---|---|---|
| Ridley-Jopling | WHO | |||
| 5 | BL | MB |
| Mild |
| 9 | BL | MB |
| Mild |
| 19 | BL | MB |
| Mild |
| 31 | BL | MB |
| Severe |
| 33 | LL | MB |
| Mild |
| 47 | BL | MB |
| Severe |
| 48 | LL | MB |
| Severe |
| 49 | LL | MB |
| Mild |
| 50 | BL | MB |
| Severe |
| 55 | BL | MB |
| Severe |
| 66 | BL | MB |
| Severe |
Note. BL bordeline lepromatous, LL lepromatous leprosy
Helminthiasis in participants and its association with leprosy type and type 2 reaction (n = 81)
| Helminth-negative n (%) | Helminth-positive n (%) | Total n (%) |
| |
|---|---|---|---|---|
| Paucibacillary | 20 (100) | 0 (0) | 20 (24.7) | 0.034 |
| Multibacillary | 50 (82) | 11 (18) | 61 (75.3) | |
| Total | 70 (86.4) | 11 (13.6) | 81 (100) | |
| No T2R | 47 (94) | 3 (6) | 50 (61.7) | 0.018 |
| T2R | 23 (74.2) | 8 (25.8) | 31 (38.3) | |
| Total | 70 (86.4) | 11 (13.6) | 81 (100) |